Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;105(3):729-735.
doi: 10.1177/13872877251331235. Epub 2025 Apr 21.

The association between pulse wave velocity and cerebrospinal fluid biomarkers for Alzheimer's disease

Hyena Kim  1 , Ambar Kulshreshtha  1   2 , Alvaro Alonso  1 , Felicia C Goldstein  3   4 , Erik Cb Johnson  3   4 , Matthew E Gold  5 , Arshed A Quyyumi  5 , James J Lah  3   4
Affiliations

The association between pulse wave velocity and cerebrospinal fluid biomarkers for Alzheimer's disease

Hyena Kim et al. J Alzheimers Dis. 2025 Jun.

Abstract

We examined the association between arterial stiffness using non-invasive pulse wave velocity (PWV) and cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers. We conducted a cross-sectional multivariate logistic regression analysis using established cut-off values for PWV and CSF biomarkers. Of the 739 participants, 69% were female, 84% were White, 12% were Black, and the mean age was 62. After adjustment for potential confounders, participants with high PWV had 94% (OR = 1.94, 95% CI 1.20-3.20) greater odds of AD biomarker positivity for tTau/Aβ42 and 108% (OR = 2.08, 95% Cl, 1.27-3.46) for pTau181/Aβ42. Our results suggest that higher arterial stiffness is associated with AD CSF biomarker positivity.

Keywords: Alzheimer's disease; arterial stiffness‌; early detection; epidemiology; non-invasive biomarkers; pulse-wave velocity; screening.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

See all similar articles

Cited by

References

    1. Matthews KA, Xu W, Gaglioti AH, et al. Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged ≥65 years. Alzheimers Dement J Alzheimers Assoc 2019; 15: 17–24. - PMC - PubMed
    1. Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimers Dis 2022; 9: 197–210. - PubMed
    1. Dyck CH van, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med 2023; 388: 9–21. - PubMed
    1. Shi M, Chu F, Zhu F, et al. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Front Aging Neurosci 2022; 14: 870517. - PMC - PubMed
    1. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012; 367: 795–804. - PMC - PubMed

LinkOut - more resources